微创医疗(00853.HK)附属心律管理业务获逾1亿美元投资
微创医疗(00853.HK)公布,连同两名投资者共斥1.05亿美元,认购旗下心律管理等业务的附属MicroPort Cardiac Rhythm Management 发行的B轮优先股。
目标公司为一间於开曼群岛注册成立的公司,并於荷兰、法国、意大利及中国设有附属公司,持有自LivaNova收购的CRM(心律管理)业务。
於完成认购事项後,附属公司於目标公司的股权将由61.24%减少至52.7%,目标公司将仍为公司的附属公司。
投资者A为目标公司的主要股东及为公司於附属公司层面的关连人士,注入新资本後,其持股由17.44%增至19.11%;投资者B为高瓴资本,将持有目标公司12.46%股权。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.